For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Pioglitazone | Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study. Pioglitigone: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study. | None | None | 0 | 1 | 0 | 1 | View |
| Bosentan | Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily. bosentan: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study. | None | None | 0 | 1 | 0 | 1 | View |